TABLE 2

Summary of preclinical efficacy of group I mGlu receptor allosteric modulators in schizophrenia-related deficits

Receptor	Type	Compound	Positive Symptom Models	Negative Symptoms Models	Cognitive Models	References
mGlu₁	PAM	VU0483605	No effect on AHL			Cho et al., 2014
		VU6004909	Attenuates AMPH-induced hyperlocomotion and disruptions in PPI	No effect on PR		Yohn et al., 2020
	NAM	FTIDC	Attenuates MHL and PPI deficits			Satow et al., 2009
		CFMTI	Reduced MHL and NMDAR antagonist-induced hyperlocomotion (NMDAR-HL) Ameliorated METH and ketamine-disrupted PPI	Reversal of MK-801-disrupted social interaction	No effect on object location memory	Satow et al., 2008
mGlu₅	PAM	CDPPB	Attenuated AMPH-induced hyperlocomotion and deficits in PPIa^,b	Attenuated MK-801-induced decrease in sucrose preferencec	↑Morris water maze learningd ↓MK-801 deficits in cognitive flexibilitye ↓PCP deficits in NOR^f	(See footnotes.)
		5PAM523	Reduced AHLg,h and NMDAR-HLh		↑Contextual CF² ↑NORh	(See footnotes.)
		VU0409551	Reverses MK-801-induced hyperlocomotion		↑Working memory/executive function in the DNMTP task ↑contextual CF deficits in SR^−/− mice	Rook et al., 2015

AHL, amphetamine-induced hyperlocomotion; AMPH, amphetamine; CF, fear conditioning; DNMTP, delayed nonmatching to position; HL, hyperlocomotion; METH, methamphetamine; MHL, METH-induced hyperlocomotion; NOR, novel object recognition; SR, serine racemase-deficient.
^aKinney et al., 2003.
^bLindsley et al., 2005.
^cVardigan et al., 2010.
^dAyala et al., 2009.
^eStefani and Moghaddam, 2010.
^fHorio et al., 2013.
^gParmentier-Batteur et al., 2014.
^hRook et al., 2015.